EYWN Stock Overview
Develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for EYWN from our risk checks.
My Notes
Capture your thoughts, links and company narrative
bioMérieux S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €101.70 |
| 52 Week High | €110.50 |
| 52 Week Low | €88.90 |
| Beta | 0.23 |
| 1 Month Change | 3.14% |
| 3 Month Change | -5.22% |
| 1 Year Change | 2.11% |
| 3 Year Change | -19.19% |
| 5 Year Change | 26.97% |
| Change since IPO | 281.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| EYWN | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -0.3% | -1.6% | 0.3% |
| 1Y | 2.1% | -9.1% | 6.9% |
Return vs Industry: EYWN exceeded the German Medical Equipment industry which returned -7.5% over the past year.
Return vs Market: EYWN underperformed the German Market which returned 7.2% over the past year.
Price Volatility
| EYWN volatility | |
|---|---|
| EYWN Average Weekly Movement | 3.1% |
| Medical Equipment Industry Average Movement | 6.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: EYWN has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: EYWN's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1963 | 13,696 | Pierre Boulud | www.biomerieux.com |
bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated Identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST Gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDASB·R·A·H·M·S PCTTM, a specific marker of severe bacterial infections/sepsis. It also provides Biomérieux vision suite, a software that provides actionable information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE Monoplex PCR tests; NUCLISENS ranges, a product for automation of the molecular biology laboratory and extraction; EMAG system For DNA and RNA extraction; ESTREAM, an automated preparation station for samples to process PCR tests; GENE-UP and VERIFLOW ranges for detection of microorganisms for the food industry.
bioMérieux S.A. Fundamentals Summary
| EYWN fundamental statistics | |
|---|---|
| Market cap | €12.08b |
| Earnings (TTM) | €411.30m |
| Revenue (TTM) | €3.81b |
29.4x
P/E Ratio3.2x
P/S RatioIs EYWN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EYWN income statement (TTM) | |
|---|---|
| Revenue | €3.81b |
| Cost of Revenue | €1.69b |
| Gross Profit | €2.12b |
| Other Expenses | €1.71b |
| Earnings | €411.30m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.49 |
| Gross Margin | 55.72% |
| Net Profit Margin | 10.81% |
| Debt/Equity Ratio | 10.1% |
How did EYWN perform over the long term?
See historical performance and comparisonDividends
0.8%
Current Dividend Yield24%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 22:42 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
bioMérieux S.A. is covered by 34 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Armelle Moulin | AlphaValue |
| Gaurav Jain | Barclays |
| Samuel England | Berenberg |